Fluidigm (FLDM) Issues Quarterly Earnings Results

Fluidigm (NASDAQ:FLDM) posted its quarterly earnings results on Thursday. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07, Morningstar.com reports. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 90.07%. The firm had revenue of $32.33 million for the quarter, compared to analyst estimates of $30.55 million.

Shares of NASDAQ:FLDM traded up $0.80 on Friday, hitting $9.35. The company had a trading volume of 3,626,242 shares, compared to its average volume of 635,439. Fluidigm has a 1-year low of $4.65 and a 1-year high of $9.76. The company has a market cap of $367.64 million, a P/E ratio of -11.69 and a beta of 2.29. The company has a debt-to-equity ratio of 7.56, a current ratio of 1.85 and a quick ratio of 1.45.

In related news, insider Levin Capital Strategies, L.P. acquired 35,033 shares of the firm’s stock in a transaction on Monday, December 10th. The shares were purchased at an average cost of $7.72 per share, for a total transaction of $270,454.76. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders acquired 1,083,700 shares of company stock worth $7,387,908. Corporate insiders own 2.20% of the company’s stock.



Several hedge funds have recently added to or reduced their stakes in FLDM. BlackRock Inc. grew its stake in shares of Fluidigm by 9.1% in the fourth quarter. BlackRock Inc. now owns 2,139,878 shares of the medical research company’s stock valued at $18,445,000 after acquiring an additional 178,429 shares in the last quarter. Vanguard Group Inc grew its stake in shares of Fluidigm by 9.5% in the third quarter. Vanguard Group Inc now owns 1,410,526 shares of the medical research company’s stock valued at $10,565,000 after acquiring an additional 121,815 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Fluidigm by 9.5% in the third quarter. Vanguard Group Inc. now owns 1,410,526 shares of the medical research company’s stock valued at $10,565,000 after acquiring an additional 121,815 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Fluidigm by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,070,500 shares of the medical research company’s stock valued at $6,380,000 after acquiring an additional 118,200 shares in the last quarter. Finally, Primecap Management Co. CA grew its stake in shares of Fluidigm by 1.1% in the third quarter. Primecap Management Co. CA now owns 5,856,043 shares of the medical research company’s stock valued at $43,862,000 after acquiring an additional 64,000 shares in the last quarter. Institutional investors and hedge funds own 98.30% of the company’s stock.

Several research firms have issued reports on FLDM. Zacks Investment Research lowered shares of Fluidigm from a “hold” rating to a “strong sell” rating in a research report on Friday. BidaskClub downgraded shares of Fluidigm from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th. Janney Montgomery Scott upgraded shares of Fluidigm from a “neutral” rating to a “buy” rating in a report on Thursday, January 3rd. ValuEngine upgraded shares of Fluidigm from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Piper Jaffray Companies upgraded shares of Fluidigm from a “neutral” rating to an “overweight” rating in a report on Friday, November 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Fluidigm currently has a consensus rating of “Hold” and an average target price of $9.25.

TRADEMARK VIOLATION WARNING: This report was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://dakotafinancialnews.com/2019/02/10/fluidigm-fldm-issues-quarterly-earnings-results.html.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Featured Article: The Role of a Fiduciary and Individual Investors

Earnings History for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply